AbbVie’s Atogepant shows breakthrough results for acute migraine relief

Suffering from acute migraine? You may soon bid adieu to the debilitating headache

WHO urges rapid expansion of new HIV prevention tools amid funding crisis

Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN

Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor

Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks

The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years